Lv1
30 积分 2024-03-20 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
4小时前
待确认
Letter: Drug interaction in resmetirom times
2个月前
已完结
A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles
2个月前
已完结
Resmetirom for treatment of MASH
7个月前
已完结
Cytotoxicity of Thirdhand Smoke and Identification of Acrolein as a Volatile Thirdhand Smoke Chemical That Inhibits Cell Proliferation
8个月前
已完结
Thyroid Hormone Signaling and the Liver
1年前
已完结
Non-alcoholic fatty liver disease
1年前
已完结
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
1年前
已完结
First US drug approved for a liver disease surging around the world
1年前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1年前
已完结
皖公网安备34019202002308
